User login
Merz Licensing Agreement
Merz North America announces a licensing agreement with Brickell Biotech, Inc, for the development of a retinoid compound (BBI-3000) for the treatment of skin conditions known to be responsive to retinoid agents, such as acne and psoriasis. Under the terms of the agreement, Merz North America will assume the full cost and responsibility for future development and commercialization, initially for North America. The development of this new clinical entity demonstrates Merz’s commitment to medical dermatology. For more information, visit www.merzusa.com.
Regenica
Suneva Medical unveils a rebranded Regenica product line consisting of 3 products: Renew SPF 15 to protect skin from harmful UV rays while signaling skin’s natural repair, Replenishing Crème to hydrate skin and reverse the signs of aging, and Repair Complex to accelerate skin renewal. The rebranded line will help physicians attract patients to Multipotent Resignaling Complex (MRCx) growth factor technology. The physician-dispensed antiaging skin care line is ideal for patients looking to better target the signs of aging to see improvement in skin texture, tone, firmness, and the appearance of fine lines and wrinkles. For more information, visit www.regenica.com.
RetrinAL
Pierre Fabre Dermo-Cosmétique USA introduces Avène RetrinAL 0.05 Cream and RetrinAL 0.1 Intensive Cream to visibly reduce the signs of aging. Both products deliver 4 antiaging benefits: wrinkle reduction, radiance, skin elasticity, and skin quality (skin texture and tone). Retinaldehyde delivers a powerful and nonirritating form of vitamin A directly to the skin, boosting cell metabolism and producing an immediate corrective effect. These hypoallergenic and fragrance-free products also contain Relastide, a patented lipopeptide that helps keep collagen and elastin from becoming stiff and rigid while boosting retinaldehyde. RetrinAL 0.05 Cream treats the first signs of aging and RetrinAL 0.1 Intensive Cream delivers a higher concentration of retinaldehyde. Both RetrinAL products will be available October 2014, exclusively in physicians’ offices. For more information, visit www.aveneusa.com.
Rosaliac CC Cream
La Roche-Posay Laboratoire Dermatologique launches Rosaliac CC Cream, a daily complete tone-correcting cream with broad-spectrum sun protection factor 30 for patients with rosacea-prone skin. Rosaliac CC Cream consists of a unique blend of red, white, yellow, and black pigments to camouflage redness. The texture has been engineered to provide an optimal balance between coverage and care, providing the hydration and lightweight texture of a BB cream while delivering coverage that is comparable to a foundation. Key ingredients including Ambophenol help reduce visible redness over time. Rosaliac CC Cream is available over-the-counter at various retailers. For more information, visit www.laroche-posay.us.
If you would like your product included in Product News, please e-mail a press release to the Editorial Office at cutis@frontlinemedcom.com.
Merz Licensing Agreement
Merz North America announces a licensing agreement with Brickell Biotech, Inc, for the development of a retinoid compound (BBI-3000) for the treatment of skin conditions known to be responsive to retinoid agents, such as acne and psoriasis. Under the terms of the agreement, Merz North America will assume the full cost and responsibility for future development and commercialization, initially for North America. The development of this new clinical entity demonstrates Merz’s commitment to medical dermatology. For more information, visit www.merzusa.com.
Regenica
Suneva Medical unveils a rebranded Regenica product line consisting of 3 products: Renew SPF 15 to protect skin from harmful UV rays while signaling skin’s natural repair, Replenishing Crème to hydrate skin and reverse the signs of aging, and Repair Complex to accelerate skin renewal. The rebranded line will help physicians attract patients to Multipotent Resignaling Complex (MRCx) growth factor technology. The physician-dispensed antiaging skin care line is ideal for patients looking to better target the signs of aging to see improvement in skin texture, tone, firmness, and the appearance of fine lines and wrinkles. For more information, visit www.regenica.com.
RetrinAL
Pierre Fabre Dermo-Cosmétique USA introduces Avène RetrinAL 0.05 Cream and RetrinAL 0.1 Intensive Cream to visibly reduce the signs of aging. Both products deliver 4 antiaging benefits: wrinkle reduction, radiance, skin elasticity, and skin quality (skin texture and tone). Retinaldehyde delivers a powerful and nonirritating form of vitamin A directly to the skin, boosting cell metabolism and producing an immediate corrective effect. These hypoallergenic and fragrance-free products also contain Relastide, a patented lipopeptide that helps keep collagen and elastin from becoming stiff and rigid while boosting retinaldehyde. RetrinAL 0.05 Cream treats the first signs of aging and RetrinAL 0.1 Intensive Cream delivers a higher concentration of retinaldehyde. Both RetrinAL products will be available October 2014, exclusively in physicians’ offices. For more information, visit www.aveneusa.com.
Rosaliac CC Cream
La Roche-Posay Laboratoire Dermatologique launches Rosaliac CC Cream, a daily complete tone-correcting cream with broad-spectrum sun protection factor 30 for patients with rosacea-prone skin. Rosaliac CC Cream consists of a unique blend of red, white, yellow, and black pigments to camouflage redness. The texture has been engineered to provide an optimal balance between coverage and care, providing the hydration and lightweight texture of a BB cream while delivering coverage that is comparable to a foundation. Key ingredients including Ambophenol help reduce visible redness over time. Rosaliac CC Cream is available over-the-counter at various retailers. For more information, visit www.laroche-posay.us.
If you would like your product included in Product News, please e-mail a press release to the Editorial Office at cutis@frontlinemedcom.com.
Merz Licensing Agreement
Merz North America announces a licensing agreement with Brickell Biotech, Inc, for the development of a retinoid compound (BBI-3000) for the treatment of skin conditions known to be responsive to retinoid agents, such as acne and psoriasis. Under the terms of the agreement, Merz North America will assume the full cost and responsibility for future development and commercialization, initially for North America. The development of this new clinical entity demonstrates Merz’s commitment to medical dermatology. For more information, visit www.merzusa.com.
Regenica
Suneva Medical unveils a rebranded Regenica product line consisting of 3 products: Renew SPF 15 to protect skin from harmful UV rays while signaling skin’s natural repair, Replenishing Crème to hydrate skin and reverse the signs of aging, and Repair Complex to accelerate skin renewal. The rebranded line will help physicians attract patients to Multipotent Resignaling Complex (MRCx) growth factor technology. The physician-dispensed antiaging skin care line is ideal for patients looking to better target the signs of aging to see improvement in skin texture, tone, firmness, and the appearance of fine lines and wrinkles. For more information, visit www.regenica.com.
RetrinAL
Pierre Fabre Dermo-Cosmétique USA introduces Avène RetrinAL 0.05 Cream and RetrinAL 0.1 Intensive Cream to visibly reduce the signs of aging. Both products deliver 4 antiaging benefits: wrinkle reduction, radiance, skin elasticity, and skin quality (skin texture and tone). Retinaldehyde delivers a powerful and nonirritating form of vitamin A directly to the skin, boosting cell metabolism and producing an immediate corrective effect. These hypoallergenic and fragrance-free products also contain Relastide, a patented lipopeptide that helps keep collagen and elastin from becoming stiff and rigid while boosting retinaldehyde. RetrinAL 0.05 Cream treats the first signs of aging and RetrinAL 0.1 Intensive Cream delivers a higher concentration of retinaldehyde. Both RetrinAL products will be available October 2014, exclusively in physicians’ offices. For more information, visit www.aveneusa.com.
Rosaliac CC Cream
La Roche-Posay Laboratoire Dermatologique launches Rosaliac CC Cream, a daily complete tone-correcting cream with broad-spectrum sun protection factor 30 for patients with rosacea-prone skin. Rosaliac CC Cream consists of a unique blend of red, white, yellow, and black pigments to camouflage redness. The texture has been engineered to provide an optimal balance between coverage and care, providing the hydration and lightweight texture of a BB cream while delivering coverage that is comparable to a foundation. Key ingredients including Ambophenol help reduce visible redness over time. Rosaliac CC Cream is available over-the-counter at various retailers. For more information, visit www.laroche-posay.us.
If you would like your product included in Product News, please e-mail a press release to the Editorial Office at cutis@frontlinemedcom.com.
